CSPIA
CORT icon

Cary Street Partners Investment Advisory’s Corcept Therapeutics CORT Stock Holding History

Cary Street Partners Investment Advisory’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-250
Closed -$6.81K – 852
2023
Q3 		$6.81K Buy
+250
New +$7.24K ﹤0.01% 1406

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cary Street Partners Investment Advisory's CORT Position: Q4 2023 in Review

Cary Street Partners Investment Advisory sold out of Corcept Therapeutics (CORT) in Q4 2023, closing a stake of 250 shares — an estimated $6.81K sold.

Cary Street Partners Investment Advisory first reported a position in CORT in Q3 2023 and held it in 1 quarter. The position peaked at $6.81K in Q3 2023. 273 funds tracked by Wall St. Rank hold CORT as of Q4 2023.

  • Cary Street Partners Investment Advisory reported no remaining Corcept Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Cary Street Partners Investment Advisory sold 250 Corcept Therapeutics shares in Q4 2023, an estimated $6.81K.
  • Cary Street Partners Investment Advisory first reported a position in Corcept Therapeutics in Q3 2023 and held it in 1 quarter.
  • Cary Street Partners Investment Advisory's Corcept Therapeutics position peaked at $6.81K in Q3 2023.
  • 273 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2023.

Based on Cary Street Partners Investment Advisory's 13F filing for Q4 2023, filed 5 Feb 2024.